Pharsight

1. Austedo patents expiration

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US8524733	September, 2021	Terminated-Denied	Auspex Pharmaceuticals, Inc.	Apotex Inc.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8524733	TEVA BRANDED PHARM	Benzoquinoline inhibitors of vesicular monoamine transporter 2	Apr, 2031 (6 years from now)
US9550780	TEVA BRANDED PHARM	Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2	Sep, 2033 (9 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8524733 (Pediatric)	TEVA BRANDED PHARM	Benzoquinoline inhibitors of vesicular monoamine transporter 2	Oct, 2031 (7 years from now)
US11666566	TEVA BRANDED PHARM	Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2	Sep, 2033 (9 years from now)
US9814708	TEVA BRANDED PHARM	Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2	Sep, 2033 (9 years from now)
US9296739	TEVA BRANDED PHARM	Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2	Sep, 2033 (9 years from now)
US9233959	TEVA BRANDED PHARM	Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2	Sep, 2033 (9 years from now)
US9296739 (Pediatric)	TEVA BRANDED PHARM	Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2	Mar, 2034 (9 years from now)
US11666566 (Pediatric)	TEVA BRANDED PHARM	Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2	Mar, 2034 (9 years from now)
US9550780 (Pediatric)	TEVA BRANDED PHARM	Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2	Mar, 2034 (9 years from now)
US9233959 (Pediatric)	TEVA BRANDED PHARM	Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2	Mar, 2034 (9 years from now)
US9814708 (Pediatric)	TEVA BRANDED PHARM	Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2	Mar, 2034 (9 years from now)
US11446291	TEVA BRANDED PHARM	Methods for the treatment of abnormal involuntary movement disorders	Mar, 2036 (11 years from now)
US11648244	TEVA BRANDED PHARM	Methods for the treatment of abnormal involuntary movement disorders	Mar, 2036 (11 years from now)
US11564917	TEVA BRANDED PHARM	Methods for the treatment of abnormal involuntary movement disorders	Mar, 2036 (11 years from now)
US10959996	TEVA BRANDED PHARM	Methods for the treatment of abnormal involuntary movement disorders	Mar, 2036 (11 years from now)
US11357772	TEVA BRANDED PHARM	Methods for the treatment of abnormal involuntary movement disorders	Mar, 2036 (11 years from now)
US11648244 (Pediatric)	TEVA BRANDED PHARM	Methods for the treatment of abnormal involuntary movement disorders	Sep, 2036 (12 years from now)
US11446291 (Pediatric)	TEVA BRANDED PHARM	Methods for the treatment of abnormal involuntary movement disorders	Sep, 2036 (12 years from now)
US11357772 (Pediatric)	TEVA BRANDED PHARM	Methods for the treatment of abnormal involuntary movement disorders	Sep, 2036 (12 years from now)
US10959996 (Pediatric)	TEVA BRANDED PHARM	Methods for the treatment of abnormal involuntary movement disorders	Sep, 2036 (12 years from now)
US11564917 (Pediatric)	TEVA BRANDED PHARM	Methods for the treatment of abnormal involuntary movement disorders	Sep, 2036 (12 years from now)
US11179386	TEVA BRANDED PHARM	Analogs of deutetrabenazine, their preparation and use	Mar, 2038 (13 years from now)
US11813232	TEVA BRANDED PHARM	Analogs of deutetrabenazine, their preparation and use	Mar, 2038 (13 years from now)
US11179386 (Pediatric)	TEVA BRANDED PHARM	Analogs of deutetrabenazine, their preparation and use	Sep, 2038 (14 years from now)
US11813232 (Pediatric)	TEVA BRANDED PHARM	Analogs of deutetrabenazine, their preparation and use	Sep, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-134)	Apr 03, 2024
M(M-54)	Jun 24, 2024
Pediatric Exclusivity(PED)	Dec 24, 2024
New Indication(I-751)	Aug 30, 2020
New Chemical Entity Exclusivity(NCE)	Apr 03, 2022
Orphan Drug Exclusivity(ODE)	Apr 03, 2024

Drugs and Companies using DEUTETRABENAZINE ingredient

NCE-1 date: 25 December, 2023

Market Authorisation Date: 03 April, 2017

Treatment: Treatment of tardive dyskinesia; A method of treating huntington's chorea

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
6 mg, 9 mg and 12 mg	05 Apr, 2021	2		07 Mar, 2036

Strength	Dosage	Availability
12MG	TABLET;ORAL	Prescription
6MG	TABLET;ORAL	Prescription
9MG	TABLET;ORAL	Prescription

AUSTEDO family patents

2. Loestrin 24 Fe patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5552394	TEVA BRANDED PHARM	Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy	Jul, 2014 (9 years ago)

Drugs and Companies using ETHINYL ESTRADIOL; NORETHINDRONE ACETATE ingredient

Market Authorisation Date: 17 February, 2006

Treatment: Prevention of pregnancy

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
1 mg/0.02 mg and 75 mg	17 Apr, 2006	1	01 Sep, 2009	22 Jul, 2014	Extinguished

Strength	Dosage	Availability
0.02MG;1MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued

LOESTRIN 24 FE family patents

3. Loseasonique patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP02782404A	2014-06-04	Laboratorios Léon Farma, S.A.	Revoked
EP02782404A	2014-06-03	Bröcher, Dirk Joachim	Revoked

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7615545	TEVA BRANDED PHARM	Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology	Jun, 2023 (10 months ago)
US7858605	TEVA BRANDED PHARM	Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology	Jun, 2023 (9 months ago)
US7855190	TEVA BRANDED PHARM	Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration	Dec, 2028 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Oct 24, 2011

Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient

Market Authorisation Date: 24 October, 2008

Treatment: Prevention of pregnancy

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.1 mg/0.02 mg and 0.01 mg	16 Nov, 2009	1	26 Oct, 2011	15 Jun, 2023	Eligible

Strength	Dosage	Availability
0.02MG,0.1MG;0.01MG,N/A	TABLET;ORAL	Prescription

LOSEASONIQUE family patents

4. Preven Emergency Contraceptive Kit patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6156742	TEVA BRANDED PHARM	Emergency contraceptive kit	Dec, 2020 (3 years ago)

Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient

Market Authorisation Date: 01 September, 1998

Treatment: Kit adapted and designed to provide both data on the current reproductive status of a patient and contraception for those who are not pregnant, but recently engaged in unprotected sex

Dosage: TABLET;ORAL

Strength	Dosage	Availability
0.05MG;0.25MG	TABLET;ORAL	Discontinued

PREVEN EMERGENCY CONTRACEPTIVE KIT family patents

5. Proair Digihaler patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP20172454A	2022-11-08	Vectura Limited	Granted and Under Opposition
EP19155324A	2021-06-29	Vectura Limited	Granted and Under Opposition
EP17811276A	2021-03-09	VECTURA DELIVERY DEVICES LIMITED	Opposition rejected
EP17800844A	2020-06-03	Vectura Limited	Opposition rejected
EP17800844A	2020-02-14	CHIESI FARMACEUTICI S.p.A.	Opposition rejected
EP01948660A	2014-08-22	Hexal Aktiengesellschaft	Patent maintained as amended
EP01948660A	2009-09-03	Vectura Delivery Devices Limited	Patent maintained as amended

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US10561808	October, 2018	Decision	Declan Walsh et al.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6748947	TEVA BRANDED PHARM	De-agglomerator for breath-actuated dry powder inhaler	Jun, 2021 (2 years ago)
US6701917	TEVA BRANDED PHARM	Dose counter for medicament inhaler	Jun, 2021 (2 years ago)
US6718972	TEVA BRANDED PHARM	Dose metering system for medicament inhaler	Jun, 2021 (2 years ago)
US8006690	TEVA BRANDED PHARM	Reservoir pressure system for medicament inhaler	Jun, 2021 (2 years ago)
US6871646	TEVA BRANDED PHARM	De-agglomerator for breath-actuated dry powder inhaler	Jun, 2021 (2 years ago)
US7540282	TEVA BRANDED PHARM	Reservoir pressure system for medicament inhaler	May, 2023 (11 months ago)
US9463288	TEVA BRANDED PHARM	Dry powder inhalation apparatus	May, 2025 (1 year, 28 days from now)
US10765820	TEVA BRANDED PHARM	Dry powder inhalation apparatus	May, 2025 (1 year, 28 days from now)
US8651103	TEVA BRANDED PHARM	Dry powder inhalation apparatus	Mar, 2028 (3 years from now)
US10022510	TEVA BRANDED PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	May, 2031 (7 years from now)
US9731087	TEVA BRANDED PHARM	Dose counter for inhaler having a bore and shaft arrangement	May, 2031 (7 years from now)
US10124131	TEVA BRANDED PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	May, 2031 (7 years from now)
US9216260	TEVA BRANDED PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	Jun, 2031 (7 years from now)
US10561808	TEVA BRANDED PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	Jan, 2032 (7 years from now)
US8978966	TEVA BRANDED PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	Jan, 2032 (7 years from now)
US9782551	TEVA BRANDED PHARM	Compliance monitoring module for a breath-actuated inhaler	Aug, 2035 (11 years from now)
US9782550	TEVA BRANDED PHARM	Compliance monitoring module for a breath-actuated inhaler	Aug, 2035 (11 years from now)
US10918816	TEVA BRANDED PHARM	Compliance monitoring module for a breath-actuated inhaler	Dec, 2035 (11 years from now)
US10569034	TEVA BRANDED PHARM	Compliance monitoring module for a breath-actuated inhaler	Aug, 2036 (12 years from now)
US11351317	TEVA BRANDED PHARM	Drug delivery device with electronics	Feb, 2038 (13 years from now)
US11357935	TEVA BRANDED PHARM	Drug delivery device with electronics	Sep, 2038 (14 years from now)
US11000653	TEVA BRANDED PHARM	Inhaler	Dec, 2038 (14 years from now)
US11344685	TEVA BRANDED PHARM	Drug delivery device with electronics	Sep, 2039 (15 years from now)
US11439777	TEVA BRANDED PHARM	Drug delivery device with electronics	May, 2040 (16 years from now)
US11464923	TEVA BRANDED PHARM	Inhaler system	Jun, 2040 (16 years from now)
US11173259	TEVA BRANDED PHARM	Drug delivery device with electronics and power management	Jul, 2040 (16 years from now)
US11266796	TEVA BRANDED PHARM	Inhalation device with integrated electronics	Feb, 2041 (16 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Mar 12, 2018
New Patient Population(NPP)	Apr 28, 2019

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 21 December, 2018

Treatment: NA

Dosage: POWDER, METERED;INHALATION

Strength	Dosage	Availability
EQ 0.09MG BASE/INH	POWDER, METERED;INHALATION	Prescription

PROAIR DIGIHALER family patents

6. Proair Hfa patents expiration

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US10561808	October, 2018	Decision	Declan Walsh et al.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5605674	TEVA BRANDED PHARM	Medicinal aerosol formulations	Feb, 2014 (10 years ago)
US8834849	TEVA BRANDED PHARM	Medicinal aerosols and methods of delivery thereof	Jun, 2017 (6 years ago)
US7566445	TEVA BRANDED PHARM	Medicinal aerosols and methods of delivery thereof	Jun, 2017 (6 years ago)
US6446627	TEVA BRANDED PHARM	Inhaler dose counter	Dec, 2017 (6 years ago)
US7105152	TEVA BRANDED PHARM	Suspension aerosol formulations	Sep, 2023 (7 months ago)
US8132712	TEVA BRANDED PHARM	Metered-dose inhaler	Sep, 2028 (4 years from now)
US10022510	TEVA BRANDED PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	May, 2031 (7 years from now)
US10695512	TEVA BRANDED PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	May, 2031 (7 years from now)
US10022509	TEVA BRANDED PHARM	Dose counter for inhaler having a bore and shaft arrangement	May, 2031 (7 years from now)
US11395889	TEVA BRANDED PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	May, 2031 (7 years from now)
US10086156	TEVA BRANDED PHARM	Dose counter for inhaler and method for counting doses	May, 2031 (7 years from now)
US9463289	TEVA BRANDED PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	May, 2031 (7 years from now)
US9808587	TEVA BRANDED PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	May, 2031 (7 years from now)
US10561808	TEVA BRANDED PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	Jan, 2032 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Sep 16, 2011

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 29 October, 2004

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.09 mg base per actuation	18 May, 2012	1	24 Feb, 2020	12 Sep, 2023	Non-Forfeiture Deferred

Strength	Dosage	Availability
EQ 0.09MG BASE/INH	AEROSOL, METERED;INHALATION	Prescription

PROAIR HFA family patents

7. Proair Respiclick patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP19155324A	2021-06-29	Vectura Limited	Granted and Under Opposition
EP01948660A	2014-08-22	Hexal Aktiengesellschaft	Patent maintained as amended
EP01948660A	2009-09-03	Vectura Delivery Devices Limited	Patent maintained as amended

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US10561808	October, 2018	Decision	Declan Walsh et al.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6446627	TEVA BRANDED PHARM	Inhaler dose counter	Dec, 2017 (6 years ago)
US6871646	TEVA BRANDED PHARM	De-agglomerator for breath-actuated dry powder inhaler	Jun, 2021 (2 years ago)
US6748947	TEVA BRANDED PHARM	De-agglomerator for breath-actuated dry powder inhaler	Jun, 2021 (2 years ago)
US6701917	TEVA BRANDED PHARM	Dose counter for medicament inhaler	Jun, 2021 (2 years ago)
US8006690	TEVA BRANDED PHARM	Reservoir pressure system for medicament inhaler	Jun, 2021 (2 years ago)
US6718972	TEVA BRANDED PHARM	Dose metering system for medicament inhaler	Jun, 2021 (2 years ago)
US7540282	TEVA BRANDED PHARM	Reservoir pressure system for medicament inhaler	May, 2023 (11 months ago)
US9463288	TEVA BRANDED PHARM	Dry powder inhalation apparatus	May, 2025 (1 year, 28 days from now)
US10765820	TEVA BRANDED PHARM	Dry powder inhalation apparatus	May, 2025 (1 year, 28 days from now)
US8651103	TEVA BRANDED PHARM	Dry powder inhalation apparatus	Mar, 2028 (3 years from now)
US9731087	TEVA BRANDED PHARM	Dose counter for inhaler having a bore and shaft arrangement	May, 2031 (7 years from now)
US10022510	TEVA BRANDED PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	May, 2031 (7 years from now)
US10124131	TEVA BRANDED PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	May, 2031 (7 years from now)
US9216260	TEVA BRANDED PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	Jun, 2031 (7 years from now)
US10561808	TEVA BRANDED PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	Jan, 2032 (7 years from now)
US8978966	TEVA BRANDED PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	Jan, 2032 (7 years from now)
US9782550	TEVA BRANDED PHARM	Compliance monitoring module for a breath-actuated inhaler	Aug, 2035 (11 years from now)
US9782551	TEVA BRANDED PHARM	Compliance monitoring module for a breath-actuated inhaler	Aug, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Mar 12, 2018
New Patient Population(NPP)	Apr 28, 2019

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 21 December, 2018

Treatment: NA

Dosage: POWDER, METERED;INHALATION

Strength	Dosage	Availability
EQ 0.09MG BASE/INH	POWDER, METERED;INHALATION	Prescription

PROAIR RESPICLICK family patents

8. Qnasl patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP11779089A	2016-01-22	FRKelly	Opposition rejected

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5605674	TEVA BRANDED PHARM	Medicinal aerosol formulations	Feb, 2014 (10 years ago)
US5683677	TEVA BRANDED PHARM	Medicinal aerosol formulations	Nov, 2014 (9 years ago)
US5776432	TEVA BRANDED PHARM	Beclomethasone solution aerosol formulations	Jul, 2015 (8 years ago)
US7780038	TEVA BRANDED PHARM	Dispensing apparatus with dosage counter	Jan, 2027 (2 years from now)
US10188811	TEVA BRANDED PHARM	Nasal spray device	Oct, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Strength(NS)	Dec 17, 2017
New Product(NP)	Mar 23, 2015

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Market Authorisation Date: 17 December, 2014

Treatment: NA

Dosage: AEROSOL, METERED;NASAL

Strength	Dosage	Availability
0.08MG/ACTUATION	AEROSOL, METERED;NASAL	Prescription
0.04MG/ACTUATION	AEROSOL, METERED;NASAL	Prescription

QNASL family patents

9. Quartette patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8450299	TEVA BRANDED PHARM	Methods of hormonal treatment utilizing ascending-dose extended cycle regimens	Oct, 2025 (1 year, 5 months from now)
US8415332	TEVA BRANDED PHARM	Methods of hormonal treatment utilizing ascending-dose extended cycle regimens	Mar, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Mar 28, 2016

Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient

Market Authorisation Date: 28 March, 2013

Treatment: Prevention of pregnancy

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mg	10 Jul, 2013	1			Extinguished

Strength	Dosage	Availability
0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	TABLET;ORAL	Prescription

QUARTETTE family patents

10. Qvar 40 patents expiration

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US10561808	October, 2018	Decision	Declan Walsh et al.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5605674	TEVA BRANDED PHARM	Medicinal aerosol formulations	Feb, 2014 (10 years ago)
US5683677	TEVA BRANDED PHARM	Medicinal aerosol formulations	Nov, 2014 (9 years ago)
US5776432	TEVA BRANDED PHARM	Beclomethasone solution aerosol formulations	Jul, 2015 (8 years ago)
US6446627	TEVA BRANDED PHARM	Inhaler dose counter	Dec, 2017 (6 years ago)
US10022510	TEVA BRANDED PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	May, 2031 (7 years from now)
US11395889	TEVA BRANDED PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	May, 2031 (7 years from now)
US9808587	TEVA BRANDED PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	May, 2031 (7 years from now)
US10695512	TEVA BRANDED PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	May, 2031 (7 years from now)
US10022509	TEVA BRANDED PHARM	Dose counter for inhaler having a bore and shaft arrangement	May, 2031 (7 years from now)
US9463289	TEVA BRANDED PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	May, 2031 (7 years from now)
US10086156	TEVA BRANDED PHARM	Dose counter for inhaler and method for counting doses	May, 2031 (7 years from now)
US10561808	TEVA BRANDED PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	Jan, 2032 (7 years from now)

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Market Authorisation Date: 15 September, 2000

Treatment: Treatment of asthma

Dosage: AEROSOL, METERED;INHALATION

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
40 mcg/actuation and 80 mcg/actuation	10 Jan, 2020	1		18 May, 2031

Strength	Dosage	Availability
0.04MG/INH Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	AEROSOL, METERED;INHALATION	Discontinued

QVAR 40 family patents

11. Qvar 80 patents expiration

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US10561808	October, 2018	Decision	Declan Walsh et al.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5605674	TEVA BRANDED PHARM	Medicinal aerosol formulations	Feb, 2014 (10 years ago)
US5683677	TEVA BRANDED PHARM	Medicinal aerosol formulations	Nov, 2014 (9 years ago)
US5776432	TEVA BRANDED PHARM	Beclomethasone solution aerosol formulations	Jul, 2015 (8 years ago)
US6446627	TEVA BRANDED PHARM	Inhaler dose counter	Dec, 2017 (6 years ago)
US10022510	TEVA BRANDED PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	May, 2031 (7 years from now)
US11395889	TEVA BRANDED PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	May, 2031 (7 years from now)
US9808587	TEVA BRANDED PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	May, 2031 (7 years from now)
US9463289	TEVA BRANDED PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	May, 2031 (7 years from now)
US10695512	TEVA BRANDED PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	May, 2031 (7 years from now)
US10086156	TEVA BRANDED PHARM	Dose counter for inhaler and method for counting doses	May, 2031 (7 years from now)
US10022509	TEVA BRANDED PHARM	Dose counter for inhaler having a bore and shaft arrangement	May, 2031 (7 years from now)
US10561808	TEVA BRANDED PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	Jan, 2032 (7 years from now)

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Market Authorisation Date: 15 September, 2000

Treatment: Treatment of asthma

Dosage: AEROSOL, METERED;INHALATION

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
40 mcg/actuation and 80 mcg/actuation	10 Jan, 2020	1		18 May, 2031

Strength	Dosage	Availability
0.08MG/INH Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	AEROSOL, METERED;INHALATION	Discontinued

QVAR 80 family patents

12. Seasonale patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE39861	TEVA BRANDED PHARM	Methods of extended use oral contraception	Jun, 2017 (6 years ago)
US5898032	TEVA BRANDED PHARM	Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy	Jun, 2017 (6 years ago)

Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient

Market Authorisation Date: 05 September, 2003

Treatment: Prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception; Prevention of pregnancy

Dosage: TABLET;ORAL

Strength	Dosage	Availability
0.03MG;0.15MG	TABLET;ORAL	Prescription

SEASONALE family patents

13. Seasonique patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP02782404A	2014-06-04	Laboratorios Léon Farma, S.A.	Revoked
EP02782404A	2014-06-03	Bröcher, Dirk Joachim	Revoked

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7615545	TEVA BRANDED PHARM	Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology	Jun, 2023 (10 months ago)
US7858605	TEVA BRANDED PHARM	Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology	Jun, 2023 (9 months ago)
US7320969	TEVA BRANDED PHARM	Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology	Jan, 2024 (2 months ago)
US7855190	TEVA BRANDED PHARM	Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration	Dec, 2028 (4 years from now)

Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient

Market Authorisation Date: 25 May, 2006

Treatment: Prevention of pregnancy; Prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception

Dosage: TABLET;ORAL

SEASONIQUE family patents

14. Vantrela Er patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9572803	TEVA BRANDED PHARM	Abuse resistant drug formulation	Sep, 2027 (3 years from now)
US9216176	TEVA BRANDED PHARM	Abuse resistant drug formulation	Sep, 2027 (3 years from now)
US8445018	TEVA BRANDED PHARM	Abuse resistant drug formulation	Jul, 2029 (5 years from now)

Drugs and Companies using HYDROCODONE BITARTRATE ingredient

Market Authorisation Date: 17 January, 2017

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

VANTRELA ER family patents

15. Zecuity patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6745071	TEVA BRANDED PHARM	Iontophoretic drug delivery system	Feb, 2023 (1 year, 1 month ago)
US8155737	TEVA BRANDED PHARM	Pharmacokinetics of iontophoretic sumatriptan administration	Apr, 2027 (2 years from now)
US8597272	TEVA BRANDED PHARM	Pharmacokinetics of iontophoretic sumatriptan administration	Apr, 2027 (2 years from now)
US8470853	TEVA BRANDED PHARM	Transdermal methods and systems for the delivery of anti-migraine compounds	Apr, 2027 (2 years from now)
US9427578	TEVA BRANDED PHARM	Pharmacokinetics of iontophoretic sumatriptan administration	Apr, 2027 (2 years from now)
US7973058	TEVA BRANDED PHARM	Transdermal methods and systems for the delivery of anti-migraine compounds	Apr, 2027 (2 years from now)
US9272137	TEVA BRANDED PHARM	Transdermal methods and systems for the delivery of anti-migraine compounds	Sep, 2027 (3 years from now)
US8366600	TEVA BRANDED PHARM	Polyamine enhanced formulations for triptan compound iontophoresis	Apr, 2029 (5 years from now)
US8983594	TEVA BRANDED PHARM	Electronic control of drug delivery system	Nov, 2030 (6 years from now)
US9327114	TEVA BRANDED PHARM	User-activated self-contained co-packaged iontophoretic drug delivery system	Oct, 2032 (8 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosage Form(NDF)	Jan 17, 2016

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 17 January, 2013

Treatment: Method for treating acute migraine in adults, with or without aura, comprising iontophoretic transdermal delivery of sumatriptan or a salt thereof; Method for treating acute migraine in adults, with ...

Dosage: SYSTEM;IONTOPHORESIS

Pharsight

Teva Branded Pharm patents expiration

1. Austedo patents expiration

AUSTEDO family patents

2. Loestrin 24 Fe patents expiration

LOESTRIN 24 FE family patents

3. Loseasonique patents expiration

LOSEASONIQUE family patents

4. Preven Emergency Contraceptive Kit patents expiration

PREVEN EMERGENCY CONTRACEPTIVE KIT family patents

5. Proair Digihaler patents expiration

PROAIR DIGIHALER family patents

6. Proair Hfa patents expiration

PROAIR HFA family patents

7. Proair Respiclick patents expiration

PROAIR RESPICLICK family patents

8. Qnasl patents expiration

QNASL family patents

9. Quartette patents expiration

QUARTETTE family patents

10. Qvar 40 patents expiration

QVAR 40 family patents

11. Qvar 80 patents expiration

QVAR 80 family patents

12. Seasonale patents expiration

SEASONALE family patents

13. Seasonique patents expiration

SEASONIQUE family patents

14. Vantrela Er patents expiration

VANTRELA ER family patents

15. Zecuity patents expiration

ZECUITY family patents

Related content

Strength	Dosage	Availability
30MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
15MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
45MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
60MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
90MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued